Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion

Molecular Pharmacology

Volumn 78, Issue 4, 2010, Pages 588-599

  Zimin, Pavel I ^b   Garic, Bojan ^a   Bodendiek, Silke B ^b   Mahieux, Cédrick ^b   Wulff, Heike ^b   Zhorov, Boris S ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 PHENOXYBUTOXY)PSORALEN; COUMARIN; IMMUNOSUPPRESSIVE AGENT; POTASSIUM CHANNEL KV1.3; POTASSIUM ION; UNCLASSIFIED DRUG; VERAPAMIL; CATION; LIGAND; POTASSIUM; POTASSIUM CHANNEL BLOCKING AGENT; VOLTAGE GATED POTASSIUM CHANNEL;

AMINO ACID SEQUENCE; ARTICLE; CHELATION; DRUG BINDING SITE; HYDROPHOBICITY; LYMPHOCYTE; MOLECULAR DOCKING; MOLECULAR MODEL; MONTE CARLO METHOD; PATCH CLAMP; PRIORITY JOURNAL; SOLVATION; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; HUMAN; MOLECULAR GENETICS; MOUSE; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; CATIONS; CELL LINE; HUMANS; KV1.3 POTASSIUM CHANNEL; LIGANDS; MICE; MOLECULAR SEQUENCE DATA; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; PROTEIN STRUCTURE, SECONDARY;

EID: 77957226984     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.064014     Document Type: Article

References (56)

1. Aiyar J, Nguyen AN, Chandy KG, and Grissmer S (1994) The P-region and S6 of Kv3.1 contribute to the formation of the ion conduction pathway. Biophys J 67:2261-2264. (Pubitemid 24369648)
2. Armstrong CM (1971) Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons. J Gen Physiol 58:413-437.
3. Armstrong CM and Binstock L (1965) Anomalous rectification in the squid giant axon injected with tetraethylammonium chloride. J Gen Physiol 48:859-872.
4. Azam P, Sankaranarayanan A, Homerick D, Griffey S, and Wulff H (2007) Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 127:1419-1429. (Pubitemid 46762978)
5. Baell JB, Gable RW, Harvey AJ, Toovey N, Herzog T, Hänsel W, and Wulff H (2004) Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J Med Chem 47:2326-2336. (Pubitemid 38478856)
6. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, et al. (2006) Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103:17414-17419.
7. Bodendiek SB, Mahieux C, Hänsel W, and Wulff H (2009) 4-Phenoxybutoxy-substituted heterocycles-a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. Eur J Med Chem 44:1838-1852.
8. Brock MW, Mathes C, and Gilly WF (2001) Selective open-channel block of Shaker (Kv1) potassium channels by s-nitrosodithiothreitol (SNDTT). J Gen Physiol 118: 113-134.
9. Brooks CL, Pettitt BM, and Karplus M (1985) Structural and energetic effects of truncating long ranged interactions in ionic polar fluids. J Chem Phys 83:5897-5908.
10. Bruhova I and Zhorov BS (2007) Monte Carlo-energy minimization of correolide in the Kv1.3 channel: possible role of potassium ion in ligand-receptor interactions. BMC Struct Biol 7:5.
11. Cahalan MD, Chandy KG, DeCoursey TE, and Gupta S (1985) A voltage-gated potassium channel in human T lymphocytes. J Physiol 358:197-237. (Pubitemid 15150542)
12. + channels as targets for specific immunomodulation. Trends Pharmacol Sci 25:280-289.
13. Cheng RC, Tikhonov DB, and Zhorov BS (2009) Structural model for phenylalkylamine binding to L-type calcium channels. J Biol Chem 284:28332-28342.
14. Cheng RC and Zhorov BS (2010) Docking of calcium ions in proteins with flexible side chains and deformable backbones. Eur Biophys J 39:825-838.
15. D'Angelo P and Persson I (2004) Structure of the hydrated and dimethyl sulfoxide solvated rubidium ions in solution. Inorg Chem 43:3543-3549.
16. Decher N, Kumar P, Gonzalez T, Pirard B, and Sanguinetti MC (2006) Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. Mol Pharmacol 70:1204-1211.
17. Decher N, Pirard B, Bundis F, Peukert S, Baringhaus KH, Busch AE, Steinmeyer K, and Sanguinetti MC (2004) Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels. J Biol Chem 279:394-400. (Pubitemid 38044838)
18. + channel and its structural implications. Nature 403:321-325.
19. Dewar MJ, Zoebisch EG, Healy EF, and Stewart JJ (1985) AM1: a new general purpose quantum mechanical model. J Am Chem Soc 107:3902-3907.
20. Domene C and Sansom MS (2003) Potassium channel, ions, and water: simulation studies based on the high resolution X-ray structure of KcsA. Biophys J 85:2787-2800. (Pubitemid 37345773)
21. Dreker T and Grissmer S (2005) Investigation of the phenylalkylamine binding site in hKv1.3 (H399T), a mutant with a reduced C-type inactivated state. Mol Pharmacol 68:966-973. (Pubitemid 41345788)
22. + channel by tetrabutylammonium: insights from X-ray crystallography, electrophysiology and replica-exchange molecular dynamics simulations. J Mol Biol 365:649-662.
23. Garden DP and Zhorov BS (2010) Docking flexible ligands in proteins with a solvent exposure- and distance-dependent dielectric function. J Comput Aided Mol Des 24:91-105.
24. Hamilton KL, Syme CA, and Devor DC (2003) Molecular localization of the inhibitory arachidonic acid binding site to the pore of hIK1. J Biol Chem 278:16690-16697.
25. Harvey AJ, Baell JB, Toovey N, Homerick D, and Wulff H (2006) A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. J Med Chem 49:1433-1441. (Pubitemid 43271896)
26. 2. Acta Crystallogr B 28:2279-2287.
27. Hockerman GH, Peterson BZ, Johnson BD, and Catterall WA (1997) Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol 37:361-396.
28. Lazaridis T and Karplus M (1999) Effective energy function for proteins in solution. Proteins 35:133-152.
29. Lenaeus MJ, Vamvouka M, Focia PJ, and Gross A (2005) Structural basis of TEA blockade in a model potassium channel. Nat Struct Mol Biol 12:454-459.
30. Li Z and Scheraga HA (1987) Monte Carlo-minimization approach to the multiple-minima problem in protein folding. Proc Natl Acad Sci USA 84:6611-6615.
31. + channel. Science 309:897-903.
32. Meeder T and Ulbricht W (1987) Action of benzocaine on sodium channels of frog nodes of Ranvier treated with chloramine-T. Pflugers Arch 409:265-273.
33. Mitcheson JS, Chen J, Lin M, Culberson C, and Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333.
34. O'Reilly AO, Khambay BP, Williamson MS, Field LM, Wallace BA, and Davies TG (2006) Modelling insecticide-binding sites in the voltage-gated sodium channel. Biochem J 396:255-263.
35. + channel occurs by a cooperative mechanism. Biophys J 69:896-903.
36. Rauer H and Grissmer S (1996) Evidence for an internal phenylalkylamine action on the voltage-gated potassium channel Kv1.3. Mol Pharmacol 50:1625-1634.
37. Sanguinetti MC and Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463-469.
38. Schmalhofer WA, Bao J, McManus OB, Green B, Matyskiela M, Wunderler D, Bugianesi RM, Felix JP, Hanner M, Linde-Arias AR, et al. (2002) Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties. Biochemistry 41:7781-7794.
39. Schmalhofer WA, Slaughter RS, Matyskiela M, Felix JP, Tang YS, Rupprecht K, Kaczorowski GJ, and Garcia ML (2003) Di-substituted cyclohexyl derivatives bind to two identical sites with positive cooperativity on the voltage-gated potassium channel, K(v)1.3. Biochemistry 42:4733-4743.
40. Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, and Wulff H (2005) Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 68:1254-1270.
41. 5. Acta Chem Scand A 39:153-156.
42. Tikhonov DB, Bruhova I, and Zhorov BS (2006) Atomic determinants of state-dependent block of sodium channels by charged local anesthetics and benzocaine. FEBS Lett 580:6027-6032.
43. Tikhonov DB and Zhorov BS (2007) Sodium channels: ionic model of slow inactivation and state-dependent drug binding. Biophys J 93:1557-1570.
44. Tikhonov DB and Zhorov BS (2008) Molecular modeling of benzothiazepine binding in the L-type calcium channel. J Biol Chem 283:17594-17604.
45. Tikhonov DB and Zhorov BS (2009) Structural model for dihydropyridine binding to L-type calcium channels. J Biol Chem 284:19006-19017.
46. Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hänsel W, and Chandy KG (2004) Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol 65:1364-1374.
47. Weiner SJ, Kollman PA, Case DA, Singh UC, and Chio C (1984) A new force field for molecular mechanical simulation of nucleic acids and proteins. J Am Chem Soc 106:765-784.
48. Weiner SJ, Kollman PA, Nguen DT, and Case DA (1986) An all atom force field for simulations of proteins and nucleic acids. J Comput Chem 7:230-252.
49. Wulff H, Gutman GA, Cahalan MD, and Chandy KG (2001) Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1. J Biol Chem 276:32040-32045. (Pubitemid 33657573)
50. Wulff H and Pennington M (2007) Targeting effector memory T-cells with Kv1.3 blockers. Curr Opin Drug Discov Devel 10:438-445. (Pubitemid 47093127)
51. Wulff H and Zhorov BS (2008) K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev 108:1744-1773. (Pubitemid 351796408)
52. Zhorov BS (1981) Vector method for calculating derivatives of energy of atom-atom interactions of complex molecules according to generalized coordinates. J Struct Chem 22:4-8.
53. Zhorov BS (1983) Vector method for calculating derivatives of the energy deformation of valence angles and torsion energy of complex molecules according to generalized coordinates. J Struct Chem 23:649-655.
54. Zhou M, Morais-Cabral JH, Mann S, and MacKinnon R (2001a) Potassium channel receptor site for the inactivation gate and quaternary amine inhibitors. Nature 411:657-661. (Pubitemid 32531662)
55. Zhou P, Tian F, Lv F, and Shang Z (2009) Geometric characteristics of hydrogen bonds involving sulfur atoms in proteins. Proteins 76:151-163.
56. + channel-Fab complex at 2.0 A resolution. Nature 414:43-48.